[go: up one dir, main page]

BRPI0815846A2 - método para reforçar a imunogenicidade de uma vacina em um indivíduo. - Google Patents

método para reforçar a imunogenicidade de uma vacina em um indivíduo.

Info

Publication number
BRPI0815846A2
BRPI0815846A2 BRPI0815846A BRPI0815846A BRPI0815846A2 BR PI0815846 A2 BRPI0815846 A2 BR PI0815846A2 BR PI0815846 A BRPI0815846 A BR PI0815846A BR PI0815846 A BRPI0815846 A BR PI0815846A BR PI0815846 A2 BRPI0815846 A2 BR PI0815846A2
Authority
BR
Brazil
Prior art keywords
immunogenicity
vaccine
enhancing
individual
Prior art date
Application number
BRPI0815846A
Other languages
English (en)
Inventor
Serra Vincent
Original Assignee
Wittycell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wittycell filed Critical Wittycell
Publication of BRPI0815846A2 publication Critical patent/BRPI0815846A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
BRPI0815846A 2007-08-29 2008-08-29 método para reforçar a imunogenicidade de uma vacina em um indivíduo. BRPI0815846A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96873107P 2007-08-29 2007-08-29
PCT/IB2008/003016 WO2010023498A1 (en) 2007-08-29 2008-08-29 Methods of enhancing adjuvanticity of vaccine compositions

Publications (1)

Publication Number Publication Date
BRPI0815846A2 true BRPI0815846A2 (pt) 2017-05-30

Family

ID=42061962

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815846A BRPI0815846A2 (pt) 2007-08-29 2008-08-29 método para reforçar a imunogenicidade de uma vacina em um indivíduo.

Country Status (14)

Country Link
US (1) US8916164B2 (pt)
EP (1) EP2190475B1 (pt)
JP (1) JP5539890B2 (pt)
KR (1) KR101540081B1 (pt)
CN (1) CN101820909A (pt)
AU (1) AU2008360937B9 (pt)
BR (1) BRPI0815846A2 (pt)
ES (1) ES2558157T3 (pt)
HR (1) HRP20151356T1 (pt)
PL (1) PL2190475T3 (pt)
PT (1) PT2190475E (pt)
RU (1) RU2491090C2 (pt)
WO (1) WO2010023498A1 (pt)
ZA (1) ZA201001477B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008350531B2 (en) 2007-12-05 2014-01-23 Abivax Use of glycosylceramides for enhancing the immune response to antigens
MY171201A (en) 2012-04-26 2019-10-01 Riken New carbamate glycolipid and use thereof
JP2024512318A (ja) 2021-03-01 2024-03-19 ディシジュアス セラピューティクス， インコーポレイテッド インバリアントナチュラルキラーｔ細胞を活性化するための化合物および炎症性老化細胞の排除における使用の方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242800A (en) * 1990-01-30 1993-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Receptor for pathogenic fungi
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (pt) * 1992-07-16 1995-11-01 Kirin Brewery
CA2147629C (en) * 1992-10-22 2005-03-22 Koji Akimoto Novel sphingoglycolipids and the use thereof
CN1045302C (zh) * 1993-04-15 1999-09-29 麒麟麦酒株式会社 新型(神经)鞘糖脂、含有它们的药物组合物及其用途
JPH08510729A (ja) * 1993-05-14 1996-11-12 サイテル コーポレイション 細胞接着のインヒビターとしてのシアリルＬｅ▲上ｘ▼類似体
US6054433A (en) * 1994-11-03 2000-04-25 The Regents Of The University Of California Methods and compositions for stimulating tissue growth and epithelial moisturization
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
EP0821068A3 (en) * 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
CN1121223C (zh) 1997-02-05 2003-09-17 麒麟麦酒株式会社 含有神经鞘糖脂的冷冻干燥组合物及其制造方法
US6417167B1 (en) * 1997-02-05 2002-07-09 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing shingoglycolipid and process for preparing them
DE69840528D1 (de) 1997-04-10 2009-03-19 Kyowa Hakko Kirin Co Ltd NKT-Zellenaktivatoren, die Alpha-Glycosylceramide enthalten
CA2316041A1 (en) 1997-12-30 1999-07-08 Pam Fredman Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications
WO1999041266A1 (en) * 1998-02-12 1999-08-19 Emory University Sphingolipid derivatives and their methods of use
SE9900496D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
EP1223978B9 (en) * 1999-10-12 2009-09-16 National Research Council Of Canada Archaeosomes as adjuvants and carriers for acellular vaccines to induce cytotoxic t lymphocyte (ctl) responses
US20030157113A1 (en) 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
AU2001252599A1 (en) * 2000-04-28 2001-11-12 Orient Cancer Therapy Co., Ltd. Remedies for cancer
JP4410913B2 (ja) * 2000-06-12 2010-02-10 壽製薬株式会社 新規糖脂質誘導体の製造方法
AU2001268564A1 (en) * 2000-06-22 2002-01-02 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
AU2001286636A1 (en) * 2000-08-25 2002-03-13 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
JP2005500336A (ja) 2001-07-25 2005-01-06 ニューヨーク・ユニバーシティ 感染および癌に対するワクチンのためのアジュバントとしてのグリコシルセラミドの使用
KR100549866B1 (ko) 2001-08-22 2006-02-08 고려대학교 산학협력단 암치료 및 예방 제제
RU2360699C2 (ru) * 2001-10-03 2009-07-10 Новартис Вэксинес Энд Дайэгностикс Инк. Композиции менингококковых вакцин с адъювантами
CA2469406A1 (en) * 2001-11-06 2003-05-15 Orient Cancer Therapy Co., Ltd. Anticancer compositions
US7273853B2 (en) * 2002-05-13 2007-09-25 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
WO2003105769A2 (en) 2002-06-13 2003-12-24 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
AU2003225891A1 (en) 2003-03-20 2004-11-19 Brigham Young University 6"-amino-6"-deoxygalactosylceramides
US7645873B2 (en) * 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
AR056245A1 (es) * 2003-06-19 2007-10-03 Bestewil Holding Bv Membranas virales reconstituidas funcionales que contienen un coadyuvante
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
US7771726B2 (en) * 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
WO2005102049A1 (en) 2004-03-31 2005-11-03 New York University Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
KR20120116511A (ko) 2004-08-27 2012-10-22 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 면역 및 자가면역의 조절제로서의 세라마이드 유도체
DK1786439T3 (da) 2004-09-03 2010-07-12 Univ Chicago Fremgangsmåder til aktivering af NKT-celler
CA2591232C (en) * 2004-12-28 2014-10-21 The Rockefeller University Glycolipids and analogues thereof as antigens for nk t cells
PL1848813T3 (pl) 2005-01-28 2013-09-30 Univ Brigham Young Aktywacja glikolipidem bakteryjnym komórek NKT podlegających restrykcji CD1d
KR100764678B1 (ko) * 2005-07-13 2007-10-09 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
US8039670B2 (en) 2005-10-25 2011-10-18 Ludwig Institute For Cancer Research Analogs of alpha galactosyceramide and uses thereof
CA2661789C (en) 2006-04-07 2014-06-03 The Scripps Research Institute Modified .alpha.-galactosyl ceramides for staining and stimulating natural killer t cells
EP2029165B1 (en) 2006-04-27 2014-12-03 Cellid Co., Ltd B cell-based vaccine loaded with the ligand of natural killer t cell and antigen
JP5564672B2 (ja) 2006-06-30 2014-07-30 ザ スクリプス リサーチ インスティテュート アジュバント及びその使用方法
EP1938836A1 (en) 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells
KR100868959B1 (ko) 2006-12-30 2008-11-17 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는면역보조용 약학적 조성물
EP2058011A1 (en) 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
AU2008350531B2 (en) * 2007-12-05 2014-01-23 Abivax Use of glycosylceramides for enhancing the immune response to antigens
MX338827B (es) 2008-10-08 2016-05-03 Vincent Serra Composicion de vacuna para uso contra influenza.

Also Published As

Publication number Publication date
RU2491090C2 (ru) 2013-08-27
AU2008360937A1 (en) 2010-03-04
ZA201001477B (en) 2010-12-29
KR20100072211A (ko) 2010-06-30
US20100285042A1 (en) 2010-11-11
AU2008360937B9 (en) 2014-02-13
AU2008360937B2 (en) 2014-01-16
EP2190475B1 (en) 2015-10-28
AU2008360937A2 (en) 2010-04-29
KR101540081B1 (ko) 2015-07-29
RU2010111766A (ru) 2011-10-10
ES2558157T3 (es) 2016-02-02
WO2010023498A8 (en) 2010-04-15
EP2190475A1 (en) 2010-06-02
JP5539890B2 (ja) 2014-07-02
JP2011518760A (ja) 2011-06-30
PL2190475T3 (pl) 2016-04-29
WO2010023498A1 (en) 2010-03-04
US8916164B2 (en) 2014-12-23
PT2190475E (pt) 2016-02-11
HRP20151356T1 (hr) 2016-01-01
CN101820909A (zh) 2010-09-01

Similar Documents

Publication Publication Date Title
BRPI0912384A2 (pt) composição, e, método para preparar uma composição
DK2200646T3 (da) RNA-Vacciner
PL2185191T3 (pl) Szczepionki przeciwko grypie o małej zawartości dodatków
BR112012000623A2 (pt) composição de emulsão estabilizada, método, e, método para preparar uma composição de emulsão estabilizada
DK2114993T3 (da) Vaccine
IL211184A0 (en) Polyvalent vaccine
IL201782A0 (en) Vaccine
GB0717911D0 (en) Vaccine
BRPI1010617A2 (pt) uso de uma composição, composição, uso não médico da composição, e, método para preprar uma composição.
BRPI0819642A2 (pt) Método para a formação de uma dentadura para um paciente em uma única visita, e, dentadura
GB0711858D0 (en) Vaccine
ZA201004303B (en) Vaccine
BRPI0818354A2 (pt) vacina preventiva do hiv baseada em anticorpos específicos para o hiv
AP2010005166A0 (en) Vaccines
BRPI0807001A2 (pt) Formulação farmacêutica, e, método para preparação de uma formulação farmacêutica.
EP2207567A4 (en) IMMUNOGENIC FORMULATIONS
GB0700135D0 (en) Vaccine
BRPI0921578A2 (pt) vacinas unitemporais
GB0710538D0 (en) Vaccine
BRPI0815846A2 (pt) método para reforçar a imunogenicidade de uma vacina em um indivíduo.
ZA201003851B (en) Vaccine
GB0709373D0 (en) BCG-based anti-atheroma vaccine
BRPI0922173A2 (pt) preparação farmacêutica, e, método para preparar uma preparação farmacêutica
EP2136835A4 (en) vaccine
GB0707697D0 (en) Vaccine

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B25A Requested transfer of rights approved

Owner name: ABIVAX (FR)

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)